zohm @zohmbastic Twitter profile

Last Seen Profiles

@MrNoFoxGiven

@90EeFQdlD38i2s

@stwmaniax

@bokeplokalmalam

@WeirdBlox_

@BCtigerbaseball

@airnews_hyd

@bokeplokalmalam

@jiowerful

@bokeplokalmalam

@donsvensen

@FellipeFreire

@sitakke_media

@stw_pdg

@TimothyTcdsb

@hasanreda212

@dobettabbetta

@stwmaniax

@ma__zet

@stwmaniax

@ShapeShift

@stwmaniax

@quientvpanama

@Ailove1999

@graysonZ80

@ASMR_Amy

@miyu_kiyohara

@bokeplokalmalam

@jgrfc1872

@yott_723

@RosenaVald22256

@lnry41842369

@RobinsonjrDavid

@girl_dizzyfat

@stw_medan

@RanzoSD

zohm

@zohmbastic

4 months

$ASTS AST SpaceMobile price target raised to $22 from $19 at Deutsche Bank Deutsche Bank analyst Bryan Kraft raised the firm's price target on AST SpaceMobile to $22 from $19 and keeps a Buy rating on the shares after its Q1 results. The firm is reducing its 2024 revenue and

zohm

@zohmbastic

4 months

$ASTS nearly 4, and p/c ratio .18 now

1

0

6

2

9

43

zohm

@zohmbastic

5 months

$ARDX Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Ardelyx Q1 2024

1

6

36

zohm

@zohmbastic

2 years

$QUBT $QBTS $IONQ quantum computing plays. ww for call options too

3

6

33

zohm

@zohmbastic

2 months

$ASTS Shipment to Cape Canaveral planned for the first week of August with a 7-day launch window in September The first five commercial satellites are the largest-ever commercial communications arrays deployed in low Earth orbit, designed to provide cellular broadband and

zohm

@zohmbastic

2 months

$ASTS Jan 2026 20c sweep

0

13

1

6

33

zohm

@zohmbastic

2 years

REST IN PEACE Scott @BARNIMAL_

2

3

32

zohm

@zohmbastic

1 month

$LUV slow and steady

zohm

@zohmbastic

2 months

$LUV acitivst stake 7%

0

2

29

28

29

zohm

@zohmbastic

9 months

Barely made it 1 day before eoy, big thanks to all the help from many, you know who you are

7

1

30

zohm

@zohmbastic

1 month

$ASTS once in a few yr type run since May, weekly chart

zohm

@zohmbastic

4 months

$ASTS

0

2

6

1

2

30

zohm

@zohmbastic

1 year

$TGTX B. Riley Raises TG Therapeutics' Price Target to $39 From $23, Keeps Buy Rating

0

12

29

zohm

@zohmbastic

1 year

$MDXH sooner or later into the gap in regular hours hopefully

zohm

@zohmbastic

2 years

$MDXH

0

1

4

29

zohm

@zohmbastic

1 month

$ASTS UBS analyst Christopher Schoell raised the firm's price target on AST SpaceMobile to $30 from $13 and keeps a Buy rating on the shares. While UBS still sees AST SpaceMobile as a high-risk, high-reward investment, initial U.S. regulatory approval, the imminent launch of its

zohm

@zohmbastic

2 months

$ASTS Sept 30c sweep

0

2

6

1

11

28

zohm

@zohmbastic

7 months

$IOVA prev vs latest, looks like ~7.3M shs increase. no idea why they came out with 13G, not 13G/A. @Maximus_Holla

zohm

@zohmbastic

7 months

$IOVA Perceptive

0

1

7

1

5

26

zohm

@zohmbastic

2 months

$IOVA Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25

1

8

26

zohm

@zohmbastic

26 days

$LUNR LUNR Intuitive Machines Strengthens Lunar Service Capabilities with $116.9 million NASA Lunar Contract Award

0

6

25

zohm

@zohmbastic

7 months

$IOVA seeing some Jan 2026 25c sweeps

zohm

@zohmbastic

7 months

$IOVA almost 16

0

3

5

23

zohm

@zohmbastic

1 month

$ASTS B. Riley raised the firm's price target on AST SpaceMobile to $26 from $15 and keeps a Buy rating on the shares following the Q2 report. The company took advantage of strong stock performance to raise $80M, the analyst tells investors in a research note. The firm says AST

zohm

@zohmbastic

1 month

$ASTS UBS analyst Christopher Schoell raised the firm's price target on AST SpaceMobile to $30 from $13 and keeps a Buy rating on the shares. While UBS still sees AST SpaceMobile as a high-risk, high-reward investment, initial U.S. regulatory approval, the imminent launch of its

1

11

28

0

8

22

zohm

@zohmbastic

2 months

$ADAP Adaptimmune gets FDA accelerated approval of Tecelra

1

3

22

zohm

@zohmbastic

1 month

$IOVA

zohm

@zohmbastic

1 month

$IOVA 11 !

0

1

7

1

2

21

zohm

@zohmbastic

1 year

@Maximus_Holla this guy changing so many people's life, one of the couple of traders that i almost blindly follow 🐐🐐🐐

3

0

21

zohm

@zohmbastic

1 month

$ASTS 8/30 50c sweep

zohm

@zohmbastic

1 month

$ASTS after big move to 36s and pull, vwap crossing, 8/23 40c, Nov 35c sweep

0

2

0

3

21

zohm

@zohmbastic

3 months

$GOSS

zohm

@zohmbastic

3 months

$GOSS Oppenheimer PT $9

1

2

5

2

7

21

zohm

@zohmbastic

3 months

$ENVX Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced it has signed an agreement with a leading California-based technology company to provide silicon batteries and packs for a mixed reality headset. Under the terms of the

2

4

20

zohm

@zohmbastic

7 months

@Maximus_Holla $IOVA Rothbaum still #1 holder, looks like added more

zohm

@zohmbastic

7 months

$IOVA guess who is happy @Maximus_Holla . Rothbaum from former $LBIO days. #1 holder I think.

3

0

10

0

4

20

zohm

@zohmbastic

11 days

$VKTX notable calls today: Jan 85c, Sep 70c, p/c ratio .23

zohm

@zohmbastic

12 days

$VKTX MorganStanley pt 105 After data for Roche's (RHHBY) CT-996 oral weight loss drug candidate were presented at the European Association for the Study of Diabetes, or EASD, annual meeting, Morgan Stanley says a comparison of Viking Therapeutics' (VKTX) initial VK2735 data to

0

6

16

1

8

20

zohm

@zohmbastic

1 year

$INZY 13G 5.2% Millennium

1

2

20

zohm

@zohmbastic

2 months

$SGMO good recovery day

richtrades

@richtrades100

2 months

If $SGMO now odds on to receive the rest of the $PFE milestones + 200 mil. Then conservatively, mkt cap should accrete at least 60mil here. At the very least

0

5

2

19

zohm

@zohmbastic

7 months

$VTYX Point72 Cohen!! @Maximus_Holla

zohm

@zohmbastic

7 months

$VTYX Jefferies: NLRP3 data could drive renewed focus on Ventyx candidates

0

2

4

2

17

zohm

@zohmbastic

1 year

$XFOR thanks to dip earlier, ssr triggered

2

18

zohm

@zohmbastic

8 months

$TGTX daily curl

2

4

18

zohm

@zohmbastic

7 months

$HIMS this company real nice beat two consecutive Qs since Nov. Used to have 14 or 15 price target, we may see a few upgrades tmrw morning @Maximus_Holla

zohm

@zohmbastic

7 months

$HIMS Revenue of $872.0 million , up 65% year-over-year in 2023 Net income of $1.2 million ; Adjusted EBITDA profitability of $20.6 million in Q4 2023 Subscribers grew to 1.5 million, up 48% year-over-year in Q4 2023 Provides Q1 and full year 2024 guidance, with full year

1

5

8

2

17

zohm

@zohmbastic

2 months

$IONQ Second Quarter Results of $11.4 Million in Revenue, Exceeding High End of Guidance Range, Representing 106% Year-Over-Year Growth Secures $9 Million in Bookings, Including System Design Win with ARLIS Demonstrates Company Record Two-Qubit Native Gate

0

5

18

zohm

@zohmbastic

1 year

$TGTX holla🙃

HODOR

@Maximus_Holla

1 year

$TGTX 11 dollar holla in advance!

5

1

20

2

1

17

zohm

@zohmbastic

6 months

$VKTX Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Scheduled for 8:00 a.m.

1

3

18

zohm

@zohmbastic

2 months

$S one to watch along with $PANW off $CRWD drama

1

3

18

zohm

@zohmbastic

1 month

$IOVA eod trying

zohm

@zohmbastic

1 month

$IOVA 10.5s key above

0

8

1

18

zohm

@zohmbastic

2 years

@Maximus_Holla $ARDX

0

2

17

zohm

@zohmbastic

2 months

$NINE big block today

zohm

@zohmbastic

2 months

$NINE setting

4

1

9

1

5

17

zohm

@zohmbastic

8 months

$ADAP Aug 4 / and some ownership info

zohm

@zohmbastic

8 months

$ADAP Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

0

2

3

1

4

17

zohm

@zohmbastic

6 months

$VKTX thinking 85.8s big level, then maybe 90 100 coming @Maximus_Holla

zohm

@zohmbastic

6 months

$VKTX Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Scheduled for 8:00 a.m.

1

3

18

2

17

zohm

@zohmbastic

9 months

$CYTK nice one, 80c handsome @Maximus_Holla

zohm

@zohmbastic

9 months

$CYTK Jan 100c sweep

0

1

2

1

17

zohm

@zohmbastic

3 months

$GOSS Oppenheimer analyst Andreas Argyrides initiated coverage of Gossamer Bio with an Outperform rating and $9 price target. Gossamer's lead asset seralutinib is an inhaled tyrosine kinase inhibitor in Phase 3 development for the treatment of pulmonary arterial hypertension, or

zohm

@zohmbastic

3 months

$GOSS Oppenheimer PT $9

1

2

5

1

5

17

zohm

@zohmbastic

3 months

$ACHR Stellantis back at it

0

2

16

zohm

@zohmbastic

7 months

@Maximus_Holla $IKNA still seeing intra vol loaders

1

3

15

zohm

@zohmbastic

1 month

TRUMP SAYS IF ELECTED HE WILL COMMIT TO BRINGING MORE "ADVANCED SMALL MODULAR NUCLEAR REACTORS" ONLINE $SMR $NNE $OKLO basket

3

17

zohm

@zohmbastic

7 months

$VTYX $100M PIPE $8.95

zohm

@zohmbastic

7 months

$VTYX 9 in sight

0

4

2

4

16

zohm

@zohmbastic

5 months

$CTMX Jefferies analyst Roger Song upgraded CytomX Therapeutics (CTMX) to Buy from Hold with a price target of $8, up from $2.50, ahead of the company's expected release of initial Phase 1a data from CX-904 at 5 pm ET on May 8. Given the timing is earlier than previous guidance,

0

5

16

zohm

@zohmbastic

4 months

$BZFD Vivek

zohm

@zohmbastic

4 months

$BZFD what a move from 13D Vivek Ramaswamy

0

4

1

15

zohm

@zohmbastic

2 months

$FULC weekly view

HODOR

@Maximus_Holla

2 months

$FULC someone buying 15C for Nov.... $1.5M worth Big data in October! Ra capital , Survetta, Adage , Third rock , RTW holders here! Wooooow! @semodough @Andre_AGTC

4

3

29

0

1

16

zohm

@zohmbastic

12 days

$VKTX MorganStanley pt 105 After data for Roche's (RHHBY) CT-996 oral weight loss drug candidate were presented at the European Association for the Study of Diabetes, or EASD, annual meeting, Morgan Stanley says a comparison of Viking Therapeutics' (VKTX) initial VK2735 data to

zohm

@zohmbastic

13 days

$VKTX William Blair analyst Andy Hsieh keeps an Outperform rating on Viking Therapeutics (VKTX) after Novo Nordisk (NVO) presented Phase I trial results of amycretin in obesity. At the highest dose of 100 mg a day, administered orally, amycretin led to a placebo-adjusted

0

1

3

0

6

16

zohm

@zohmbastic

9 months

@Maximus_Holla $CYTK can i close? ty for early insight boss

2

1

16

zohm

@zohmbastic

11 months

$STNE StoneCo Q3 Adj EPS $0.27 Beats $0.22 Estimate, Sales $643.35M Beat $610.17M Estimate / Strong quarter with Adjusted EBT reaching R$545 million , up 228% year over year, on accelerating MSMB TPV growth of 19.9%, resulting in Adjusted Net income of R$435 million , up 302%

0

3

15

zohm

@zohmbastic

1 month

$LQDA Needham notes that a new filing by the FDA in United Therapeutics' (UTHR) ongoing lawsuit against FDA is drawing attention from investors in Liquidia Technologies (LQDA) and United Therapeutics. While acknowledging that the contents are unclear, the firm says that the

0

3

15

zohm

@zohmbastic

2 months

$AQST Oppenheimer analyst Francois Brisebois raised the firm's price target on Aquestive Therapeutics (AQST) to $15 from $13 and keeps an Outperform rating on the shares after the FDA announced approval of Neffy, an epinephrine nasal spray from competitor ARS Pharmaceuticals

2

8

15

zohm

@zohmbastic

2 years

$AMAM early shorts having good Friday

0

3

14

zohm

@zohmbastic

1 year

$EH EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company, announced that in anticipation of an upcoming announcement concerning a very significant development regarding its business

0

2

15

zohm

@zohmbastic

4 months

$GERN Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

0

3

15

zohm

@zohmbastic

7 months

$VINC 7s

zohm

@zohmbastic

9 months

$VINC seems getting good trend, small starter on pull the other day, need cash but management track record. prob can get more if offer, very early stage

0

1

4

2

1

14

zohm

@zohmbastic

7 months

$VTYX small gap in pre

zohm

@zohmbastic

7 months

$VTYX Ventyx to host virtual investor event on March 11 th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash equivalents and marketable securities of $252.2 million as of December

0

2

6

2

1

14

zohm

@zohmbastic

5 months

$CDTX Cidara Therapeutics reacquires rights to CD388 from Johnson & Johnson for $85M $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b

5

2

15

zohm

@zohmbastic

9 months

$CLRB Oppenheimer pt 11 from 8

0

4

14

zohm

@zohmbastic

2 months

$IOVA back to 9

zohm

@zohmbastic

3 months

$IOVA daily bounce

0

1

15

zohm

@zohmbastic

1 year

thanks to $TOP, all these china names party in AH 🍿

4

1

15

zohm

@zohmbastic

6 months

$GERN

zohm

@zohmbastic

6 months

$GERN GoldmanSachs joined to upgrade PT to $5 along with other firms

1

2

1

2

15

zohm

@zohmbastic

4 months

$TGTX great bounce today, maybe 18s key

zohm

@zohmbastic

5 months

$TGTX daily setting

1

7

2

1

15

zohm

@zohmbastic

1 year

$HOOK HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

0

3

15

zohm

@zohmbastic

7 months

$OPTN daily

HODOR

@Maximus_Holla

8 months

$OPTN basing chart since jun 2023 , seems like good R/R for run up to their pdufa which was extended! they have one approved drug already!

6

3

20

4

1

13

zohm

@zohmbastic

6 months

$CYTK big block

2

1

15

zohm

@zohmbastic

2 months

$LUMN Lumen Technologies (NYSE: LUMN) today announced it has secured $5 billion in new business driven by major demand for connectivity fueled by AI. Large companies across industry sectors are seeking to secure fiber capacity quickly, as this resource becomes increasingly

1

2

15

zohm

@zohmbastic

2 years

$AI call sweeps

0

5

14

zohm

@zohmbastic

1 year

$HRTX form4 2.49M at 1.37 also from PIPE

zohm

@zohmbastic

1 year

$HRTX 13d/a stake increase by Rubric captial 26.7M 19.0% from 11.75M 9.9%

0

2

6

0

5

14

zohm

@zohmbastic

7 months

@Maximus_Holla $ADAP hopfully follows $TCRX type daily

2

14

zohm

@zohmbastic

5 months

$ARDX not bad vol day

zohm

@zohmbastic

5 months

$ARDX Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Ardelyx Q1 2024

1

6

36

0

4

14

zohm

@zohmbastic

20 days

$ASTS 9/13 40c sweep

zohm

@zohmbastic

20 days

$ASTS Deutsche Bank Adjusts AST SpaceMobile Price Target to $63 From $22, Maintains Buy Rating

0

2

5

0

1

14

zohm

@zohmbastic

2 years

$NU Nu Holdings Q3 Sales $1.30B Beat $1.22B Estimate, Added 5.1M Customers In Quarter

2

13

zohm

@zohmbastic

11 months

$UNCY

Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for...

- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology...

finance.yahoo.com

3

1

11

zohm

@zohmbastic

6 months

$SOUN nonstop call flows today, daily break, thinking mayb 8.7s big above

zohm

@zohmbastic

7 months

$SOUN some AH action after a few stake filings, Blackrock, Softbank, also Nvida

1

3

0

3

14

zohm

@zohmbastic

20 days

$TARS very nice flow today @Maximus_Holla

HODOR

@Maximus_Holla

29 days

$TARS some hits and nice hold, had great ER... multiple high PT Barclays with 60, HCW with 61 and Oppenheimer 63! LT stock!

1

0

22

3

2

13

zohm

@zohmbastic

5 months

@Maximus_Holla $KPRX

1

2

13

zohm

@zohmbastic

1 year

$HIMS Revenue of $207.9 million, up 83% year-over-year in Q2 2023 Net loss of $7.2 million; Adjusted EBITDA profitability of $10.6 million in Q2 2023 Subscribers grew to 1.3 million, up 74% year-over-year in Q2 2023

1

2

14

zohm

@zohmbastic

9 months

fairly excited to see a publication in Nature Chemistry () / eye-opening potential cancer cell treatment by renowned James Tour group at Rice / photon to mechanical action via NIR plasmon excitation in molecules had 99% efficiency against lab cultures of

Molecular Jackhammers Eradicate Cancer Cells by Vibronic-Driven Action

Through the actuation of vibronic modes in cell-membrane-associated aminocyanines, a new type of molecular mechanical action can be exploited to rapidly kill cells by necrosis. This is done using...

www.biorxiv.org

0

14

zohm

@zohmbastic

27 days

$IREN record adj EBITA in FY24, elelctricity cost up due to hash rate, net loss narrower / Iris Energy Reports FY24 Bitcoin Mining Revenue Of $184.10M , Up From $75.5M Last Year / Iris Energy Says 2024 Guidance Remains Unchanged; Says Well On Track To Achieve 20 EH/s Milestone

1

4

14

zohm

@zohmbastic

5 months

$VTYX handsome candle @Maximus_Holla

1

14

zohm

@zohmbastic

7 months

$ADAP JonesResearch upgraded Adaptimmune to Buy from Hold with a $3 price target. Adaptimmune's Q4 earnings call provided incremental updates on their clinical programs as well as preparations for the potential commercial launch of afami-cel in Q3 of 2024,

zohm

@zohmbastic

7 months

$ADAP

0

2

11

0

5

14

zohm

@zohmbastic

9 months

$BCEL baker bros 19.99%

2

14

zohm

@zohmbastic

1 month

$ASTS

0

1

14

zohm

@zohmbastic

1 month

$IMNN seems low risk vs recent low

0

1

14

zohm

@zohmbastic

1 year

$SFR made a few $

zohm

@zohmbastic

1 year

$SFR quite some % run

0

2

5

0

13

zohm

@zohmbastic

20 days

$CORZ Needham PT 16 / We are initiating coverage of Core Scientific (CORZ) with a buy rating & $16 PT. CORZ is the first mover (among bitcoin miners) in what we expect will be a fast growing, high demand environment for high-performance compute (HPC) data center capacity. We

1

3

13

zohm

@zohmbastic

26 days

$LUNR 15min chart, near prev high

zohm

@zohmbastic

26 days

$LUNR LUNR Intuitive Machines Strengthens Lunar Service Capabilities with $116.9 million NASA Lunar Contract Award

0

6

25

0

2

13

zohm

@zohmbastic

1 year

@Maximus_Holla $INZY will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentation on Monday, April 17 at the European Calcified Tissue Society Congress

0

1

13

zohm

@zohmbastic

7 months

$IONQ March 11c sweep @Maximus_Holla

zohm

@zohmbastic

7 months

@Maximus_Holla $IONQ

1

0

4

1

13

zohm

@zohmbastic

1 year

$HRTX

1

2

13

zohm

@zohmbastic

9 months

$RKLB On December 21, 2023, Rocket Lab USA, Inc. (the “Company”), through its wholly owned subsidiary Rocket Lab National Security, entered into an agreement with a United States government customer (“Customer”) to design, manufacture, deliver, and operate 18 space vehicles. The

0

4

13

zohm

@zohmbastic

4 months

$ERAS blocks no joke today @Maximus_Holla

zohm

@zohmbastic

4 months

$ERAS another block 1M at 2.7

0

1

2

1

12

zohm

@zohmbastic

1 year

$ARDX

zohm

@zohmbastic

1 year

$ARDX back to 4.8s zone

0

10

0

4

13

zohm

@zohmbastic

1 year

$IMGN Truist Securities Adjusts Price Target on ImmunoGen to $18 From $15, Maintains Buy Rating / ImmunoGen price target raised to $20 from $9 at Barclays

1

4

13

zohm

@zohmbastic

9 months

$IOVA wen 10? @Maximus_Holla

zohm

@zohmbastic

11 months

$IOVA nice daily bounce

1

0

4

1

13

zohm

@zohmbastic

4 months

$ADAP Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

1

5

13

zohm

@zohmbastic

10 months

$CCCC looks like some folks under water @Maximus_Holla

4

1

13

zohm

@zohmbastic

2 years

$SI 15c in the money now

zohm

@zohmbastic

2 years

$SI Blackrock stake increase from 1.87M 6.3% to 2.28M 7.2% per 13G/A

0

1

8